Alessandra Fabi
YOU?
Author Swipe
View article: Digital Integration of Narrative Medicine and Patient-Reported Outcome Measures to Improve Understanding of Quality of Life in Metastatic Breast Cancer: The PERGIQUAL Study
Digital Integration of Narrative Medicine and Patient-Reported Outcome Measures to Improve Understanding of Quality of Life in Metastatic Breast Cancer: The PERGIQUAL Study Open
Purpose This observational, prospective study aimed to evaluate the feasibility and usefulness of a Person-based Care (PbC) digital pathway integrating Narrative Medicine (NM) and e-PROMs for patients with metastatic breast cancer; the sec…
View article: Identification of an immune-metabolic biosignature linking depressive symptoms and breast cancer in a clinical population
Identification of an immune-metabolic biosignature linking depressive symptoms and breast cancer in a clinical population Open
Breast cancer (BC) is a leading cause of mortality among women. Comorbidity with mood disorders is a condition either disregarded or underdiagnosed in BC patients, but that might ultimately jeopardize health trajectories. This is supported…
View article: HER2 intratumoral heterogeneity predicts response to neoadjuvant therapy in HER2-positive breast cancer: impact and interplay with HER3 expression
HER2 intratumoral heterogeneity predicts response to neoadjuvant therapy in HER2-positive breast cancer: impact and interplay with HER3 expression Open
Intratumoral heterogeneity (ITH) of HER2 expression and HER3 upregulation have been associated with resistance to HER2-targeted therapies. However, their predictive role in the neoadjuvant setting remains controversial. We retrospectively …
View article: Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer Open
Background In the development of breast cancer (BC) and ovarian cancer (OC) there may be an influence of lifestyle and environmental factors. This influence could be relevant also in patients with genetic predisposition such as in carriers…
View article: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial Open
Neoadjuvant T-DXd-THP demonstrated statistically significant and clinically meaningful pCR benefit and improved safety versus ddAC-THP.
View article: Validation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer
Validation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer Open
Background Cancer-related fatigue (CRF) is a common symptom in patients with locally advanced or metastatic breast cancer (LA/M BC) receiving taxane-based chemotherapy (CT). CRF is commonly assessed as a subjective experience by patient qu…
View article: Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy
Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy Open
View article: Weight Changes during Early Breast Cancer Treatment and Their Association with Survival: An Exploratory Functional Data Analysis of GIM-2 Trial
Weight Changes during Early Breast Cancer Treatment and Their Association with Survival: An Exploratory Functional Data Analysis of GIM-2 Trial Open
Introduction Limited evidence is available on the impact of early breast cancer (EBC) treatments on body weight. Notably, robust data quantifying the magnitude and timing of weight changes during treatment are lacking, and existing finding…
View article: HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations
HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations Open
Mechanistic relationships between heat shock protein 90 (HSP90) and human epidermal growth factor receptor 2 (HER2) are complex and clinical correlations in breast cancer remain inconsistent. We investigated the role of HSP90 expression in…
View article: Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM) Open
View article: 390P Predictors of outcome with trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (HER2+ aBC): A multicentric, cohort study (DeReal-REST)
390P Predictors of outcome with trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (HER2+ aBC): A multicentric, cohort study (DeReal-REST) Open
View article: 236P Bone health (BH) and endocrine therapy (ET) in premenopausal early breast cancer (eBC): A real-life monocenter experience with denosumab
236P Bone health (BH) and endocrine therapy (ET) in premenopausal early breast cancer (eBC): A real-life monocenter experience with denosumab Open
View article: Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan Open
Background Metastatic triple-negative breast cancer (BC; mTNBC) is one of the most aggressive cancers, difficult to treat due to the absence of hormone target receptors. Sacituzumab govitecan (SG) is a new therapeutic approach that exploit…
View article: Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors Open
Mesenchymal tumors of the breast constitute a rare and heterogeneous group of neoplasms, representing only 0.5% to 1% of all breast tumors. Originating from mesenchymal tissues, these tumors include various histological subtypes. They are …
View article: Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Change of Molecular Subtype at Re-Biopsy. Insights from the GIM-13 - AMBRA Study
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Change of Molecular Subtype at Re-Biopsy. Insights from the GIM-13 - AMBRA Study Open
Introduction: The treatment of MBC patients is guided by receptor status, with re-biopsy at relapse recommended to reassess hormone receptor (HR) status. Various treatment options are available for HER2- MBC, including CDK4/6 inhibitors, P…
View article: Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice Open
Introduction Evaluation of every breast cancer (BC) patient by multidisciplinary team and application of guidelines are very important to ensure the best treatment and achieve the best outcome. Methods The multicenter prospective observati…
View article: Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study Open
Among Luminal-HER2 negative early BCs, our results do not support a clear predictive and prognostic effect of HER2 status, although a trend of worse pCR and better survival for HER2 low BCs cannot be ruled out.
View article: Prognostic implications of risk definitions from the monarchE and NATALEE trials
Prognostic implications of risk definitions from the monarchE and NATALEE trials Open
Background The monarchE and NATALEE trials employed different high-risk inclusion criteria. The main objective is to assess prognostic differences based on their inclusion criteria. Methods Patients with hormone receptor-positive/HER2-nega…
View article: Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy Open
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR) is …
View article: Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives Open
Mesenchymal tumors of the breast represent a rare and diverse group of neoplasms, accounting for 0.5% of all breast tumors. These tumors originate from the mesenchymal tissues of the breast and encompass a variety of histological subtypes.…
View article: Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan Open
View article: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world Open
View article: Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer Open
View article: The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study
The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study Open
View article: Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer
Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer Open
Triple negative breast cancer (TNBC) is an aggressive type of breast cancer. While most TNBCs are initially sensitive to chemotherapy, a substantial fraction acquires resistance to treatments and progresses to more advanced stages. Here, w…
View article: Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study Open
View article: Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial Open
View article: Outcomes of Radiotherapy in Oligoprogressive Breast Cancer
Outcomes of Radiotherapy in Oligoprogressive Breast Cancer Open
Introduction: Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario. Methods…
View article: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study Open
View article: Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients Open